24/7 Market News Snapshot 13 January, 2025 – Ardelyx, Inc. (NASDAQ:ARDX)

January 13, 2025

DENVER, Colo., 13 January, 2025 (247marketnews.com) – (NASDAQ:ARDX) are discussed in this article.
Ardelyx, Inc. (ARDX) has experienced a significant uptick in its stock performance, reflecting growing investor interest. Opening at $5.06, shares have risen to $5.845, marking an increase of approximately 15.29% from a previous close of $5.07. This rise comes amid heightened trading activity, with current volumes reaching 8.38 million shares. As the company navigates this positive momentum, technical analysis shows potential support near the $5.07 mark and resistance at the psychological threshold of $6.00. Investors are advised to monitor indicators such as the Relative Strength Index (RSI) and Moving Average Convergence Divergence (MACD) to evaluate potential overbought conditions and adjust risk management strategies accordingly.

Amid this buoyant market response, Ardelyx is also celebrating remarkable commercial success, projecting total U.S. net product sales for 2024 to reach approximately $319 million (unaudited). This accomplishment emphasizes the robust demand for its innovative therapies, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor), with peak sales for IBSRELA expected to surpass $1 billion annually. CEO Mike Raab highlighted the firm’s commitment to meeting the growing patient need for advanced therapeutic options, demonstrated through the uptake of its products. IBSRELA alone has generated an estimated $158 million in sales for the year, with approximately $54 million expected in Q4, showcasing a sustained growth trajectory.

Simultaneously, XPHOZAH has gained traction with projected sales of around $161 million, bolstered by approximately $57 million in the fourth quarter. Expectations suggest peak sales for this medication could reach $750 million as it continues to address hyperphosphatemia effectively. With around $250 million in cash and cash equivalents, Ardelyx is strategically positioning itself for continued growth and advancement of its product pipeline, underscoring its dedication to improving patient outcomes through innovative therapies. The company is set to share further insights at the upcoming 42nd Annual J.P. Morgan Healthcare Conference, reaffirming its commitment to operational excellence and market leadership.

Related news for (ARDX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.